SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination ...

On September 7, the moon will turn a coppery red during an 82-minute eclipse, one of the most widely seen celestial shows of the decade. A coppery moon glows above Waterton Lakes National Park in ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

Rachel Ho is a rising 10th-grader at Langley High School in McLean. She loves writing and thinks she might want to follow in her mother’s footsteps and study at the University of Virginia. To get a ...

Learn how to use pattern-matching features in your Java programs, including pattern matching with switch statements, when clauses, sealed classes, and a preview of primitive type pattern matching in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

Eclipse Private Wealth was in the inaugural class of Sanctuary's Enterprise Partner Program, developed to support the inorganic growth efforts of its Partner Firms. Eclipse is a highly sophisticated ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...